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Abstract:  87 
Background:  88 
Increasing obesity related health conditions have a substantial burden on population health and 89 
healthcare spending.  Obesity may have a sex-specific impact on disease development, men and women 90 
may respond differently to interventions, and there may be sex-specific differences to the cost-91 
effectiveness of interventions to address obesity.  There is no clear indication of cost-effective 92 
treatments for men.   93 
 94 
Methods:  95 
This systematic review summarises the literature reporting the cost-effectiveness of non-surgical 96 
weight-management interventions for men.  Studies were quality assessed against a checklist for 97 
appraising decision modelling studies. 98 
 99 
Results: 100 
Although none of the included studies explicitly set out to determine the cost-effectiveness of treatment 101 
for men, seven studies reported results for subgroups of men.  Interventions were grouped into lifestyle 102 
interventions (five studies) and Orlistat (two studies).  The retrieved studies showed promising evidence 103 
of cost-effectiveness, especially when interventions were targeted at high-risk groups, such as those 104 
with impaired glucose tolerance.   There appears to be some sex-specific elements to cost-effectiveness, 105 
however, there were no clear trends or indications of what may be contributing to this.   106 
 107 
Conclusion: 108 
The economic evidence was highly uncertain, and limited by variable methodological quality of the 109 
included studies.  It was therefore not possible to draw strong conclusions on cost-effectiveness.  Future 110 
studies are required to demonstrate the cost-effectiveness of interventions specifically targeted towards 111 
weight loss for men.  112 
 113 
INTRODUCTION: 114 
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 115 
Overweight and obesity are significant population health concerns.  US data from 2007-2010 show that 116 
based on having a BMI (Body Mass Index) ≥ 30kg/m2, 34.4% of men and 36.1% of women were obese 117 
[1].  In England in 2011, 24% of men and 26% of women were obese, however 65% of men and 58% 118 
of women were overweight [2].  Projections from the UK Foresight report [3] show that men will 119 
overtake women for obesity (47% and 36% respectively by 2025).  However, morbid obesity (BMI ≥ 120 
40kg/m2) tends to be less prevalent in men than women [2] [4].    Worldwide, there is a substantial sex 121 
and geographical effect to obesity trends.  Increases in BMI for men have generally tended to be greatest 122 
in high income countries (especially USA and UK).  However, for women, increases in BMI have been 123 
greatest in southern and central Latin American countries [5]. Reasons for the sex and country specific 124 
interactions in trends are not immediately clear, however the data re-enforce the importance of 125 
developing interventions targeted by region and sex. 126 
 127 
Obesity in men is a risk factor for a very wide range of diseases impacting on health and quality of life.  128 
Most notably are the increased risks of cardiovascular disease, diabetes and cancers which can be 129 
attributed in part to obesity.  Men with BMI ≥ 30kg/m2 and waist circumference ≥ 102cm have an 130 
increased risk of at least one symptom of impaired physical, psychological or sexual function, and these 131 
symptoms are also more likely in men with raised waist circumference (≥ 102 cm), but BMI < 30kg/m2 132 
[6] [7] . Evidence is clear that for the whole population, obesity related health conditions are responsible 133 
for a significant proportion of national health spending. This economic burden is only likely to increase 134 
over time, given increasing obesity rates worldwide.  If past trends continue, there could be 65 million 135 
more obese people in the US, and 11 million more in the UK, by 2030 [8].  The associated combined 136 
medical costs of treating preventable diseases attributed to rising obesity trends were estimated to 137 
increase by $48-$66 billion per year and by £1.9-£2 billion per year in the United States of America 138 
(USA) and UK by 2030, respectively, representing at least2% of UK annual healthcare spending [8].  139 
 140 
Furthermore, based on these trends, the UK could lose 6,300,000 Quality Adjusted Life Years (QALYs) 141 
by 2030 as a result of the rising obesity problem [8].  The same study predicted that a 1% reduction in 142 
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BMI for every adult, based on baseline values could save 3,195,000 QALYs by 2030 [8].  Despite some 143 
uncertainty in the literature regarding the assumptions underpinning the future trends in obesity 144 
worldwide [9] [10], there is general consensus that obesity rates will continue to increase into the near 145 
future, with significant impact, not only on health care costs, but also on population health, quality of 146 
life and the social, economic and emotional costs to those individuals affected.  147 
 148 
The burden of obesity on healthcare and wider economic costs has motivated the evaluation of clinical 149 
effectiveness and cost-effectiveness of a range of treatment strategies, including drug therapy, surgery, 150 
diet and physical activity, all of which have been shown to have varying degrees of success, regardless 151 
of sex, in modifying the obesity problem.  Recent systematic reviews have summarized the current 152 
literature on the long term cost-effectiveness of obesity prevention interventions generally [11], and the 153 
cost-effectiveness of therapeutic interventions [12].   154 
 155 
This purpose of this article is to report an updated systematic review of the cost-effectiveness of non-156 
surgical treatments in the management of obesity in men and to summarize the literature on this 157 
important topic.  The original work formed part of a larger research project funded by the National 158 
Institute for Health Research (NIHR) Health Technology Assessment (HTA) program [13], which 159 
reviewed the clinical and cost-effectiveness and qualitative literature on obesity management for men, 160 
since men are much less likely to take part in trials or evaluations of weight loss interventions [14].  161 
This report [13] found clear evidence that policy makers should take account of sex and gender 162 
differences when designing services for obesity management, and that design differences between men 163 
and women may influence uptake, effectiveness, dropout rates and costs.   164 
This article reports the costs, outcomes and cost-effectiveness of a range of strategies for the 165 
management of obesity in adult men, with an appropriate quality assessment of the included studies, 166 
based on best practice economic evaluation methodology.   167 
METHODS: 168 
 169 
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Identification of studies: 170 
 171 
An extensive and highly sensitive search strategy using appropriate subject headings and text word 172 
terms was developed to identify alternative strategies for weight loss, with a distinct and interpretable 173 
focus on strategies for the management of obesity in adult men [13].  The literature search included 174 
both ongoing studies and grey literature.  Databases searched were:  MEDLINE (1946 –October 2014); 175 
MEDLINE-in-Process (24th October 2014); Embase (1974 – October 2014); Health Management 176 
Information Consortium (1979 – October 2014); National Health Service (NHS) Economic Evaluations 177 
Database; Cost-effectiveness Analysis Registry; Research Papers in Economics (all searched up to 178 
October 2014).  No language restrictions were imposed, however the search was limited to studies 179 
published post 1990. Full details of the search strategy used for the MEDLINE and Embase databases 180 
are presented in Appendix 1 to the paper.  Further details of the search strategies for other databases are 181 
available from the authors on request. 182 
 183 
Inclusion and exclusion criteria: 184 
 185 
Economic evaluations, with full description of economic methods and results conducted alongside 186 
randomized trials and de novo decision analytical models that comparatively analyzed costs and 187 
outcomes in an economic evaluation framework were included.  Methodological papers, review papers, 188 
cost of illness papers and studies which did not conduct a formal comparison of costs and outcomes 189 
(i.e. those studies which did not conduct a full economic evaluation) were excluded.  A full economic 190 
evaluation was defined as a cost-utility analysis, cost-effectiveness analysis, cost-benefit analysis or 191 
cost-minimisation analysis framework.  We excluded studies from this review which reported limited 192 
cost-effectiveness outcomes, as the primary purpose of the publication was to present clinical results.  193 
Such studies were excluded as they would not present methods and / or results in sufficient detail, and 194 
we could not quality assess the study.   195 
 196 
9 
 
Studies were included if they reported results either wholly or for a sub-group of men (mean or median 197 
age of 16 years or over, with no upper age limit). Studies particularly examining men with obesity 198 
related to psychotropic medication, diagnosed eating disorder or with learning disabilities were 199 
excluded.  The following interventions were included: Orlistat (but not Sibutramine or Rimonabant, 200 
which no longer have European Medicines Agency licenses); diet; physical activity; behaviour change 201 
relating to weight loss; or combinations of any of these. Complementary therapies, surgical procedures 202 
and other medications were excluded.  Economic evaluation studies were only included if their main 203 
aim was to evaluate the cost-effectiveness of weight loss interventions.  Studies examining 204 
combinations of interventions, other than the combinations outlined above, were not included.  For 205 
example, we did not include interventions combining smoking cessation with weight loss.  Studies were 206 
therefore deemed fit for inclusion in the review if they were full economic evaluations producing weight 207 
loss, where results were reported solely or for sub-groups of men. 208 
 209 
Study selection, data extraction and reporting 210 
 211 
Data extraction was undertaken by the project health economist (DB).  Data extraction forms were 212 
checked by a second member of the review team (AA) for consistency and accuracy.  The data 213 
extraction process focused on two key areas: (i) the results of the economic evaluations in terms of 214 
estimates of costs and effects; and (ii) the methods used to derive the results.  Summary data from each 215 
study are reported and a narrative discussion is presented.  The aim of the narrative is to identify 216 
common results, methodological strengths and weaknesses across interventions and to inform future 217 
applied and methodological research.   Due to the wide variation in reported currencies and costing 218 
years, we have inflated costs from the study year of reporting to 2014 values using appropriate inflation 219 
indices for each individual country [15] [16], and converted to UK £, using purchasing parity indices 220 
provided by the Organization for Economic Co-operation and Development (OECD) for non-UK 221 
studies[17].  The presentation of data from the studies in common year and currency estimates is to 222 
facilitate a discussion of the results across broad intervention groups, but is not intended in any way to 223 
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represent a formal quantitative synthesis of the data.  All included studies were quality assessed using 224 
the Philipp’s checklist for decision modelling in economic evaluations [18]. 225 
 226 
Reporting of economic evaluations: 227 
 228 
Included studies report costs, outcomes and synthesize these estimates within a formal economic 229 
evaluation framework.  Economic evaluations are based on the principles of scarcity and choice.  Many 230 
healthcare interventions may improve patient outcomes.  However, healthcare resources are scarce, and 231 
so decision makers have to make choices on the best way to spend their limited health budgets.  232 
Economic evaluation is a way in which we can attempt to allocate money to health care interventions 233 
in the most efficient way possible, gaining maximum health outcome with restricted investment.  There 234 
are two main methods of economic evaluation which have been included in this review, namely cost-235 
effectiveness analyses (CEA) and cost-utility analyses (CUA).  Both present a comparison of the 236 
additional costs of a new intervention with the improvement in outcomes.  Results are usually presented 237 
in terms of the Incremental Cost-Effectiveness Ratio (ICER), which is simply given as [(Cost of new 238 
intervention – Cost of standard) / (Outcomes of new intervention – outcomes of standard)].  Lower 239 
values of the ICER are preferred as they offer better value for money.  The difference between CEA 240 
and CUA lies in how outcomes are measured.  For CEA, outcomes are measured in terms of natural 241 
units, such as life years gained, reduced cases of diabetes etc.  For CUA, outcomes are typically 242 
measured in terms of QALYs, which combine benefits in reduced mortality with a measure of quality 243 
of life.  QALYs are the preferred outcome measure for decision making bodies such as the National 244 
Institute for Health & Care Excellence (NICE), the European Network for technology assessment 245 
(EUnetHTA), the Canadian Agency for Drugs and Technology in Health (CADTH) and other decision 246 
making bodies as they provide a common metric for the comparison of new interventions across the 247 
health services.  Each country and decision making body will have their own criteria for recommending 248 
interventions as cost-effective.  For example, NICE typically recommend interventions for 249 
reimbursement in the UK if the cost of achieving a one unit improvement in QALYs is less than £30,000 250 
((i.e. an ICER < £30,000 per QALY) [19].  Further, if an intervention which improves QALYs is found 251 
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to also generate long term cost savings, for example if cost savings achieved from reducing long term 252 
incidence of coronary heart disease were greater than the costs of intervening now, then this offers an 253 
even stronger case for cost-effectiveness and is reported as being cost saving or the “dominant” 254 
intervention in the analysis.  As obesity is a predictor for the development of chronic health conditions, 255 
we are interested not only in short term outcomes from randomized controlled trials (RCTs), but also 256 
in the longer-term costs and outcomes associated with differential risks of developing chronic diseases 257 
such as diabetes and heart disease.  It is therefore common economic evaluation practice to extrapolate 258 
short-term outcomes from clinical trials (e.g. blood pressure, cholesterol levels, BMI) to longer term 259 
health outcomes, such as risk of disease and mortality as well as the healthcare costs associated with 260 
such diseases over a patient’s lifetime.  In order to make these predictions, economic evaluations 261 
typically use decision analytical models, often Markov models, which estimate future costs and 262 
outcomes attributable to an intervention based on the probability of developing diseases into the future.  263 
This extrapolation of costs and outcomes forms an important tool in economists’ evaluation of 264 
healthcare interventions.   265 
 266 
  267 
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RESULTS: 268 
 269 
Original searches of the literature were conducted to 2012 and updated to 2014.  In total, the primary 270 
searches identified 2,333 potentially relevant titles and abstracts, 90 studies were selected for full text 271 
retrieval to further assess their eligibility criteria for our study.  Upon reading all full text papers, a total 272 
of seven studies [20] [21] [22] [23] [24] [25] [26] were deemed to meet our inclusion criteria and were 273 
formally included for the review and quality assessment.   A flow chart of included studies from the 274 
original review is available from the original project report [13].  Due to study heterogeneity, we did 275 
not undertake formal meta-analysis of results.  Therefore, a narrative discussion of the cost-276 
effectiveness results is presented with included studies grouped into two categories: 1) studies that focus 277 
on lifestyle interventions (5 studies [20] [21] [23] [25] [26]) and 2) studies that focus on Orlistat 278 
pharmacotherapy (2 studies [22] [24]).  In addition to the included studies, we retrieved two further 279 
clinical guideline documents [27] [28] from NICE, the first of which briefly discusses sex-specific 280 
issues in the cost-effectiveness or Orlistat [27], with the latter guidance relating to the management of 281 
overweight and obese adults through lifestyle weight management services [28].  Detailed study 282 
characteristics, interventions and comparator treatments evaluated in the studies are presented in Table 283 
1 whilst the main cost-effectiveness results are presented in Table 2. 284 
 285 
Lifestyle interventions: 286 
 287 
Segal and colleagues [21] found that a group diet and physical activity behavioural modification 288 
intervention for men, was both cost saving to health services and also more effective than providing no 289 
routine care, thus demonstrating favourable cost-effectiveness results.  The intervention was most cost-290 
effective when restricted to those at greatest risk of type II diabetes (i.e. those with impaired glucose 291 
tolerance).  The study conclusions were robust to plausible variation in the treatment success rate of the 292 
programme.   293 
 294 
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Olsen and colleagues [23] found that General Practitioner (GP) counselling was more cost-effective 295 
than dietician provided counselling to encourage weight loss and reduce the risk of developing 296 
ischaemic heart disease (IHD) or death.  It should be noted however that there were important 297 
differences in the content of the advice provided to the different groups.  GP advice included general 298 
broad lifestyle advice and the delivery of commercially available information on healthy diet, whereas 299 
dietician provided advice was more focussed and concentrated on the principles of good nutrition.   300 
The authors speculate that favourable results for GP consultations may be driven by the additional 301 
general health advice which they routinely provided.  Despite the cost-effectiveness results favouring 302 
GP over dietician support, the authors conclude that the role of the dietician should not be discounted, 303 
especially given health care provider constraints in practice. 304 
 305 
Galani and colleagues [20] found that a structured lifestyle intervention (including regular dietician 306 
visits and supervised exercise sessions), delivered to overweight and obese adults over the course of 307 
three years was dominant (cost saving and more effective) for borderline obese and was also highly 308 
cost-effective for overweight and obese men, with low ICERs, offering excellent value for money to 309 
health services providers.  Results were also robust to sensitivity analyses, adding to the strength of the 310 
study’s conclusions. 311 
 312 
Miners and colleagues [25] evaluated an e-learning device with tailored feedback to participants over a 313 
lifetime horizon using a discrete event simulation model, but did not find evidence to prove cost-314 
effectiveness compared to a conventional care package including dietary and physical exercise advice.  315 
The results were highly sensitive to the cost of providing the online programme and the authors note 316 
that their conclusions should not be generalized to all web-based interventions.  317 
Spyra and colleagues [26] evaluated four alternative lifestyle interventions against a ‘do nothing’ 318 
approach.  Three commercially provided programs, involving specially trained providers, for German 319 
social health insurance funds and therapeutic nihilism (with no medical or specialist intervention) were 320 
compared.  A two phase programme of protein rich meal replacement followed by a maintenance phase 321 
with medically controlled long term specialist care was found to be the most cost-effective treatment 322 
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option.  Specific intervention details were however not provided rendering it difficult to assess the 323 
applicability or generalizability of the results. 324 
NICE Guidance on Lifestyle Interventions: 325 
 326 
NICE have also recently issued guidance on lifestyle weight management for overweight and obese 327 
adults [28], which included a review of the literature on cost-effectiveness and additional sex specific 328 
modelling of longer term costs and effects.  The results of the review showed lifestyle interventions to 329 
be cost-effective, but studies were of variable quality.  The additional modelling carried out showed 330 
that lifestyle interventions costing £100 per person for a 12 week programme, or costing £200 for a 24 331 
week programme would be cost-effective if the amount of weight lost is maintained for life.   Whilst 332 
sex was found to be an influencing factor, it was not a major driver of cost-effectiveness results.  333 
However, the model was highly sensitive to the assumptions surrounding maintenance of weight loss, 334 
showing that if weight was regained over 2 years or less, such interventions would no longer be cost-335 
effective.  The length of required weight loss maintenance required for cost-effectiveness was less for 336 
older people.  Maintenance of weight loss over time is a critical driver of cost-effectiveness, and further 337 
research is required to identify the best evidence for populating economic models.  338 
 339 
Drug treatment with Orlistat: 340 
 341 
Two studies estimated the cost-effectiveness of Orlistat in overweight and obese men.  Ianazzo and 342 
colleagues [22] reported a cost-utility analysis of Orlistat (120mg, three times daily), over a four year 343 
time period in addition to a lifestyle intervention (dietary and physical exercise components) for the 344 
prevention of type 2 diabetes, in an Italian obese population.   There was no clear evidence that Orlistat 345 
was cost-effective in overweight and obese men.  However, the results were highly sensitive to the level 346 
of risk of developing diabetes.  Therefore, the authors concluded that if the drug was targeted at a high 347 
risk group, then the treatment was much more likely to be a cost-effective use of healthcare resources.   348 
 349 
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Maetzel and colleagues [24] evaluated Orlistat 120mg taken three times daily for only one year in 350 
addition to standard treatment guidelines for type 2 diabetes (an 11 year diabetes treatment programme) 351 
in a US healthcare setting.  Standard diabetes care included pharmacotherapy (e.g. metformin) and 352 
weight management in the form of dietary and physical activity advice.  Orlistat was found to be cost-353 
effective.  However, the authors note that conclusions were highly sensitive to the duration of treatment 354 
effect, with greater duration of effect greatly improving cost-effectiveness.  Observational data to 355 
support long term use of Orlistat in this population are needed to validate the results of the study. 356 
 357 
National level Guidance on the use of Orlistat: 358 
 359 
Our review identified one clinical guideline document which evaluated the cost-effectiveness of 360 
Orlistat, and presented data separately for men and women.  The National Institute for health and Care 361 
Excellence (NICE), the UK’s decision making body for the recommendation of treatments for 362 
reimbursement on the NHS, has issued obesity guidelines (clinical guideline number 43) [27], which 363 
included an update of original NICE guidance on Orlistat (Technology Appraisal number 22) [34].  364 
Additional modelling work was undertaken to estimate sex-specific quality of life weights to inform 365 
QALY calculations, and for use in subsequent economic modelling exercises.  Sensitivity analyses 366 
reported QALY and cost per QALY outcomes separately for men, based on available effectiveness 367 
(weight loss) and cost data for Orlistat.  There was no evidence of differing cost-effectiveness for men 368 
and women based on 12 months’ treatment with Orlistat, with ICERs well below a commonly 369 
acceptable willingness to pay of £20,000 per QALY gained [19].  Differences between men and women 370 
appear to be more pronounced when evaluating longer term Orlistat treatment over 48 months.  Over 371 
this longer treatment period, the base case analysis reports higher cost per QALY for men (£29,089) 372 
compared to women (£26,917).  Within this analysis, for men, the data suggest that the greater the initial 373 
BMI, the more cost-effective Orlistat is (ICER = £29,920; BMI = 38kg/m2), with the ICER increasing 374 
to £33,134 when initial BMI is 30kg/m2.  The converse appears to be true for women: ICER = £30,155 375 
for an initial BMI = 38kg/m2; ICER = £23,982 for an initial BMI = 30kg/m2.  The results show that for 376 
the comparison of 48 vs. 12 months’ treatment with Orlistat, cost-effectiveness is dependent upon a 377 
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number of factors, including sex, baseline BMI, weight trend without Orlistat, and weight regain after 378 
treatment discontinuation.  The conclusion of the evaluation was that NICE could not recommend 48 379 
months of treatment, given the uncertainty in the ICER presented.  This appears to be the only publicly 380 
available guidance internationally which highlights the cost-effectiveness of Orlistat specifically for 381 
men. 382 
 383 
Quality assessment of the included studies: 384 
 385 
The results of all the included studies should be interpreted in light of highly variable methodological 386 
quality.  All included studies were formally quality assessed according to the Phillip’s critique for 387 
economic evaluations [18].  Five studies used Markov models to extrapolate short term outcomes over 388 
a longer time horizon and estimate cost-effectiveness [20] [21] [22] [24] [26], one used a discrete event 389 
simulation model [25] to compare the time to development of obesity related complications and oneused 390 
Cox regression modelling to estimate time to death as a measure of effectiveness [23].  However, the 391 
latter only projected long term outcomes, not costs.  This is an important omission from economic 392 
studies as cost implications to health services are likely to occur far into the future, through differing 393 
risks of developing health related complications and requiring expensive hospital care.  The disease 394 
states included in the modelling process varied depending on the study.  The most common disease 395 
states modelled were heart disease and diabetes.  Given the many health related complications 396 
associated with obesity and their chronic nature, Markov models and or discrete event simulation 397 
models, which extrapolate both costs and outcomes over a long time horizon, including for diseases 398 
other than heart disease and diabetes such as cancers and osteoarthritis, could be argued to give the most 399 
appropriate estimate of cost-effectiveness. 400 
 401 
While more sophisticated models are often preferred, it is also important to consider the underlying 402 
processes, quality of the data used to populate the model and the underlying assumptions used to 403 
estimate cost-effectiveness.  Data used within the models were generally well described and clearly 404 
referenced, though there is little evidence of formal systematic searching for data to populate the 405 
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models. Methods used to synthesize data from the literature to estimate model treatment effects were 406 
poorly described.  Only two studies detailed the meta-analysis carried out [20] [25].   407 
 408 
The costing perspective was described in all studies.  The most common perspective was that of the 409 
health services, though two studies stated a societal perspective [20] [22] and one a social health 410 
insurance perspective [26].   Intervention costs were included for all studies, and downstream costs to 411 
health services included in six out of the seven.  Despite their inclusion in the evaluations, the 412 
calculation of intervention and downstream costs was not always thoroughly reported and prevented 413 
reproducibility of the results.  Where appropriate, costs were discounted to their present day values, 414 
though only three studies tested the impact of varying discount rates on cost-effectiveness outcomes in 415 
sensitivity analyses [20] [24] [25].  416 
 417 
Effectiveness data used in the models were, for the most part, based on weight loss which was used to 418 
predict clinical outcomes such as cholesterol levels, systolic blood pressure and HbA1c levels and taken 419 
from published sources.  However, the explicit modelled link between weight loss data and clinical 420 
outcome measures has generally been poorly described.  There is also little evidence to determine 421 
whether model inputs were always based on sex-specific data.  Whilst it is clear that the goal of 422 
interventions modelled in the studies was to induce weight loss, and results were reported for men, the 423 
methods of extrapolating weight loss to long term sex specific outcomes are not always clearly 424 
presented.  Indeed, weight loss data were poorly reported generally, with even less data presented on 425 
differences in weight loss by sex.   426 
 427 
Some studies used Framingham risk equations [31] [33] to determine relative risks of cardiovascular 428 
events which were then linked, using a combination of literature and modelling exercises to final health 429 
outcomes and complications (e.g. diabetes, stroke, myocardial infarction etc.).  Again, this was 430 
completed to varying degrees of complexity and data were not always clearly reported for weight loss 431 
or gender specific model inputs.  Studies which failed to clearly report model data inputs are very 432 
difficult to generalise across groups, and would be theoretically difficult to re-produce in practice. 433 
18 
 
 434 
Three studies were cost-utility analyses [20] [22] [25], reporting results as cost per QALY gained.  Such 435 
studies may be of greatest value to decision makers as they combine quality and length of life in one 436 
single outcome.  Whilst the mortality (length of life) component was always well described, the methods 437 
used to derive utility weights were less clear.  This has important implications for the generalizability 438 
of the results, particularly in an international context.  One study reported cost per an average 439 
effectiveness score developed by the authors to reflect the importance of different grades of weight loss 440 
and the risk of developing obesity related complications [26].  The remaining three were cost-441 
effectiveness analyses, reporting cost per life year gained [21] [23] [24].   442 
 443 
Assumptions regarding the duration and continuation of treatment effect, for example weight loss and 444 
weight regain over time or changes in clinical risk factors (such as blood pressure) are crucial drivers 445 
of cost-effectiveness of weight loss interventions.  Galani and colleagues assumed that weight loss was 446 
maintained over six years, with linear regain over four [20].  Therefore, after 10 years, it was assumed 447 
weight had returned to baseline levels.  This assumption was validated against the Finnish Diabetes 448 
Prevention Study [29], however alternative assumptions were not explored in sensitivity analysis.  449 
While mortality and cardiovascular risk factors are based on sex-specific data and these are extrapolated 450 
to final outcomes, it is not clear if these were applied to sex-specific weight loss data or not.  Maetzel 451 
and colleaguesassumed that patients receiving Orlistat would have weight loss over one year of therapy 452 
after which weight regain would be linear over three years, up to a point where weight would match 453 
that of the placebo group [24].  This assumption was tested in the author’s sensitivity analysis and was 454 
found to have an important impact on cost-effectiveness results.  The remaining studies did not 455 
adequately document their assumptions about continuation of treatment effect over time.  While such 456 
information is likely to be uncertain, it is important that the impact of any assumptions is thoroughly 457 
tested in sensitivity analyses. 458 
 459 
All but one [26] of the studies attempted some form of sensitivity analysis, mainly focussing on issues 460 
of parameter uncertainty.  Heterogeneity in study results was well accounted for across studies, with 461 
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four out of five studies reporting results for key subgroups (e.g. impaired glucose tolerance (IGT), age 462 
groups, sex).  All studies reported cost-effectiveness results for men and women separately, the only 463 
exception being Maetzel and colleagues [24], for which the base case model results were specific to 464 
men.  Subgroup analyses conducted were appropriate to the study question and were generally clearly 465 
reported and interpreted.  Where multi-variable sensitivity analyses were conducted, results were not 466 
always reported separately for men and women. Three studies [20] [22] [24] conducted extensive 467 
probabilistic sensitivity analysis, with uncertainty in cost-effectiveness estimates reported as cost-468 
effectiveness acceptability curves (CEACs) and scatter plots.  Again, however, illustrations were only 469 
reported for sex-specific subgroups in one study [20].  Comprehensive conduct of sensitivity analysis 470 
is crucial to determine the strength of a study’s conclusions as well as the degree to which the results 471 
are generalizable to other setting, populations or countries. 472 
 473 
A summary of the quality assessment for each study is provided in Table 3.  More detailed comments 474 
on quality assessment forms for individual studies are available from the authors on request.   475 
 476 
 477 
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DISCUSSION    478 
 479 
To our knowledge, this is the only systematic review of studies which evaluate the cost-effectiveness of 480 
interventions for the treatment of obesity in men.  Although the studies retrieved offered some insights into 481 
the potential differences in cost-effectiveness of treatments for men and women, especially in relation to 482 
Orlistat, none of the studies specifically set out to determine sex specific cost-effectiveness results.  As a 483 
result, it is not always clear that model inputs were sex-specific.  Further, as it was not an original objective, 484 
no studies conducted the full range of sensitivity analyses on men and women separately.  It was therefore 485 
not possible to assess the full range of uncertainty in reported cost-effectiveness estimates for men and 486 
women separately.   487 
 488 
Our review does however provide some insights that these obesity treatments may offer good value for 489 
money.  This was particularly evident in studies which targeted the highest risk groups in society, such as 490 
those with impaired glucose tolerance.  Targeting these high risk groups could improve the cost-491 
effectiveness case of treatments further. However, there was insufficient evidence reported to determine 492 
whether targeting at risk men had different cost-effectiveness outcomes from targeting at risk women. 493 
 494 
Our review compliments a body of literature summarising the evidence on effectiveness and cost-495 
effectiveness of obesity interventions.  Lehnert and colleagues [11] provide a review of the cost-496 
effectiveness literature, including studies which didn’t report results separately for men and women.  They 497 
found, similarly to our review, that the majority of interventions were cost-effective, or cost-saving.  This 498 
complements the results of the studies included in our review. However caution should be noted when 499 
interpreting the broad suggestion of cost-effectiveness, as whether or not an intervention is cost-effective 500 
will be determined by the comparison which is made and the modelling for long-term weight loss 501 
maintenance.  Lehnert specifically found that modifications to a target population’s environment through 502 
fiscal and regulatory measures were the most cost-effective [11].  We found insufficient evidence to confirm 503 
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this conclusion in men only studies.  However, this is an area which warrants future research in men.  504 
Similarly to our review, Lehnert also found large uncertainty in reported cost-effectiveness results.  This 505 
renders it difficult to draw firm conclusions.  Further, study heterogeneity of interventions, comparators, 506 
modelling techniques, disease states considered and time horizon of costs and outcomes further complicate 507 
judgements about the comparative cost-effectiveness of interventions. 508 
 509 
Our review concluded that there was a paucity of literature on the cost-effectiveness of non-surgical 510 
interventions to manage obesity in men.  A recently published study reporting clinical outcome results, 511 
suggests that a community delivered intervention targeted at obese and overweight men in 13 Scottish 512 
professional football clubs offers promising results.  The Football Fans In Training (FFIT) intervention [35] 513 
may also be a cost-effective use of resources, based on a preliminary economic evaluation presented in the 514 
trial results.  However, in order to definitively determine cost-effectiveness we await the publication of 515 
results from the long term modelling exercise linked to this study.   516 
 517 
Our review was conducted to address the cost-effectiveness of lifestyle and drug interventions to treat 518 
obesity in men.  Nonetheless, surgery represents an important part in the obesity treatment pathway and is 519 
worthy of discussion.  There are clear differences in the provision of bariatric surgery depending on sex.  520 
For example, in England in 2009 / 2010 obesity surgery was more common among women (5047 521 
procedures) than men (1473 procedures) [36].    Obesity surgery has been found to be clinically and cost-522 
effective [37, 38] and may even generate long term cost savings to health services providers in terms of 523 
reduced hospital contacts over a longer period of time [39].  Although there is good evidence on cost-524 
effectiveness of bariatric surgery in the most obese population groups, the authors are unaware of any strong 525 
evidence relating to sex-specific cost-effectiveness.  Determining whether or not there is a sex-specific 526 
element to the cost-effectiveness of obesity surgery, and if so what the drivers of this difference may be, 527 
are important avenues for future research.  Robust evidence is required to determine if the current imbalance 528 
in provision of surgery by sex in the UK is a cost-effective use of scarce health services resources. 529 
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 530 
Whilst the studies included in our review point towards the cost-effectiveness of weight loss interventions, 531 
they should however be interpreted with caution and in light of their methodological limitations.  Studies 532 
included were not explicitly designed to evaluate cost-effectiveness in men alone and it was thus not 533 
possible to fully evaluate the applicability of reported results to men only subgroups.  For example, it was 534 
not always clear if data inputs were sex-specific and it was uncommon for uncertainty in men only analyses 535 
to be reported in detail.  This renders it difficult to draw strong conclusions or provide guidance to policy 536 
makers interested in sex specific policy questions.   537 
In terms of guidance for future good practice economic evaluation research, our review noted many strong 538 
and important assumptions regarding modelling of the continuation of treatment effect and weight loss 539 
maintenance over time across the studies, with no clear consensus on how this has been incorporated into 540 
the respective economic models.  Studies which assume maintenance of incremental weight loss over time 541 
for the experimental group are likely to bias the analysis greatly in favour of the experimental intervention.  542 
Studies which conducted sensitivity analysis on assumptions around continuation of treatment effect over 543 
time, showed substantial variation in the presented ICERs.  There is a clear lack of evidence on continuation 544 
of treatment effect to inform the models, however it is important that adequate sensitivity analyses are 545 
presented in order to fully inform decision makers regarding uncertainty in this important model parameter.   546 
Maintenance of treatment effect is likely to be determined mainly through adherence to lifestyle changes 547 
introduced at early stages of an intervention.  Adherence to health lifestyle is an important driver of cost-548 
effectiveness and one which has received insufficient coverage in the literature in general.  Reviews of 549 
clinical effectiveness and qualitative literature conducted in parallel to this review address alternative 550 
measures which can motivate men and encourage adherence to interventions [13].  Engaging participants 551 
with interventions being tested and ensuring adherence to the therapy under evaluation is a key component 552 
of determining an interventions effectiveness, and hence its cost-effectiveness.  Failure to engage 553 
participants in weight loss interventions can have a substantial impact on healthcare resource use, especially 554 
when rolled out to a large population of overweight or obese individuals.  The impact on cost-effectiveness 555 
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can be substantial, yet only one study in our review addressed the issue of adherence [25], finding that 556 
results were sensitive to the percentage of participants who fully adhered to the weight loss programme. 557 
 558 
The framework of the analysis is a further important point to consider in economic evaluation.  Cost-Utility 559 
analyses, reporting cost per QALY tend to be the gold standard for economic evaluation.  The advantage 560 
of  using QALYs is that they can improve the comparability of studies, and can thus be used to aid policy 561 
makers regarding resource allocation decisions.  While QALYs are commonly used for this purpose, and 562 
are recommended by NICE, they only capture the health benefits of an intervention.  There is scope for 563 
future research to consider broader measures of value, perhaps in the form of cost benefit analyses, which 564 
capture and include benefits associated with care processes and non-health outcomes.  The inclusion of 565 
broader, preference based measures of outcome, such as discrete choice experiments (DCEs), can help to 566 
generate information on what is important to patients, and what they value most. DCEs can be used to 567 
determine the attributes of the processes and outcomes of care that are important to individuals, thus helping 568 
to improve adherence and weight loss maintenance.  They can also be used in a cost-benefit analysis 569 
framework. 570 
 571 
There is an urgent need for high quality economic evaluations, addressing a research question on cost-572 
effectiveness of obesity related interventions for men.  The long term economic results from the FFIT study 573 
[35] will undoubtedly be an important contribution to this literature.  However, the target group is limited 574 
to football fans.  Further high quality studies are required to assess the value for money of other targeted 575 
weight loss interventions for men. Such studies should systematically consider the available evidence on 576 
acceptability, effectiveness and costs associated with alternative interventions.  Future research studies 577 
should be based on decision analytical models, with sex-specific model input data.  Further consideration 578 
should be given to the methods used to link the effect of weight loss to overall disease risk.  Some of our 579 
included studies seemed to suggest that small and even transient weight loss may have an impact on future 580 
disease risk and therefore could have an important impact on long-term effectiveness and cost-effectiveness 581 
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outcomes.  Maintenance of weight loss over time is an important parameter for cost-effectiveness and 582 
should be comprehensively tested in sensitivity analyses, with appropriate ranges of cost-effectiveness 583 
presented to decision makers.  In this regard, studies should explicitly consider preferences of individual 584 
groups of the population to develop targeted ways in which to improve adherence and encourage long term 585 
maintenance of weight loss.  This too will have important consequences for cost-effectiveness outcomes. 586 
 587 
CONCLUSION 588 
 589 
Our review did not identify any studies which evaluated the long term cost-effectiveness of weight loss 590 
interventions designed explicitly for men.  However, the long-term economic results from the FFIT study 591 
[35] will help to begin to bridge a gap in this literature.  There is some evidence that lifestyle interventions 592 
combining low fat (usually reducing), dietary advice and physical activity are likely to be cost-effective, 593 
and that  Orlistat may be cost-effective in addition to a lifestyle intervention, especially when targeted at 594 
those with or at greatest risk of developing type 2 diabetes (e.g. those with IGT).  However, there were no 595 
clear or systematic differences in cost-effectiveness of any of the interventions between men and women.  596 
There was insufficient evidence to draw strong conclusions on cost-effectiveness of weight loss 597 
interventions in men.  Future studies should develop interventions which specifically target men.  Economic 598 
evaluations should ensure that analyses are modelled over a sufficiently long time horizon to capture the 599 
most important costs and health outcomes attributable to weight loss interventions.  Researchers are 600 
recommended to follow best practice guidelines for the conduct of economic evaluations alongside 601 
randomized controlled trials [40] and modelling studies [18].  Following specific best practice guidelines 602 
will improve the evidence base on cost-effectiveness and ensure the best quality economic evidence is 603 
provided to policy makers targeting weight loss in men.  604 
 605 
  606 
25 
 
REFERENCES 607 
[1]  Centres for disease control and prevention.  Healthy weight, overweight and obesity among adults 
aged 20 and over, by selected characteristics: United States, selected years 2007-2010 (2012). 
[Online]. Available: http://www.cdc.gov/nchs/data/hus/2012/068.pdf. [Accessed February 2014]. 
[2]  The Health and Social Care Information Centre.  Health Survey for England - 2011, Health, 
social care and lifestyles (2012). [Online]. Available: 
http://www.ic.nhs.uk/searchcatalogue?productid=10149&returnid=1685. [Accessed February 
2014]. 
[3] Butland B, Jebb S, Kopelman P, McPherson K, Thomas S, Mardell J, Parry V.  Foresight. 
Tackling Obesities: Future Choices - Project Report 2nd edition. (2007). [Online]. Available: 
http://www.bis.gov.uk/assets/foresight/docs/obesity/17.pdf. [Accessed February 2014]. 
[4]  Bradshaw P, Bromley C, Corbett J, et al. The Scottish Health Survey, Volume 1: Adults. (2012). 
[Online]. Available: www.scotland.gov.uk/Resource/0040/00402630.pdf. [Accessed February 
2014]. 
[5]  Finucane M, Stevens G, Cowan M, et al.  National, regional and global trends in body mass index 
since 1980: systematic analysis of health examination surveys and epidemiological studies with 
960 country years and 9.1 million participants. Lancet 2012; 377: 557-67.  
[6]  Ross R, Shaw K, Rissanen J, Martel Y, De Guise J, Avruch L.  Sex differences in lean and 
adipose tissue distribution by magnetic resonance imaging: Anthropometric relationships. Am J 
Clin Nutr 1994; 59: 1277-85.  
[7]  Han T, Tajar S, O'Neill T, et al.  Impaired quality of life and sexual function in overweight and 
obese men: the European Male Ageing Study.  Eur J Endocrinol 2011; 164: 1033-11.  
[8]  Wang Y, McPherson K, Marsh T, Gortmaker S, Brown M.  Health and economic burden of the 
projected obesity trends in the USA and the UK. Lancet (2011); 378: 815-25.  
26 
 
[9]  McPherson K, Marsh T, Brown M. Foresight. Tackling obesity: future choices - modelling future 
trends in obesity and their impact on health. London: Government Office for Science, 2007.  
[10]  Flegal K, Carroll M, Ogden C, Curtin L.  Prevalence and trends in obesity among US adults, 
1999-2008. JAMA 2010; 303: 235-41.  
[11]  Lehnert T, Sonntag D, Konnopka A, Riedel-Heller S, Konig H. The long term cost-effectiveness 
of obesity prevention interventions: systematic literature review. Obesity Reviews 2012; 13: 537-
53.  
[12]  Avenell A, Broom J, Brown T, et al.  Systematic review of the long-terms effects and economic 
consequences of treatments for obesity and implications for health improvement. Health Technol 
Assess 2004; 8 (21).  
[13]  Robertson C, Archibald D, Avenell A, Douglas F, Hoddinott P, van Teijlingen E, Boyers D, 
Stewart F, Boachie C, Fioratou E, Wilkins D, Street T, Carroll P, Fowler C. Systematic reviews 
of and integrated report on the quantitative, qualitative and economic evidence base for the 
management of obesity in men. Health Technol Assess 2014; 18(35):1-424 
[14] Pagoto SL, Schneider KL, Oleski JL, Luciani JM, Bodenlos JS, Whited MC. Male inclusion in 
randomized controlled trials of lifestyle weight loss interventions. Obesity 2012;20:1234-9. 
[15]  Eurostat.  Annual Average inflation rates, 2001-2014. European Commission, 2014. [Online]. 
Available: http:// ec.europa.eu/eurostat/web/hicp/data/database. [Accessed Janurary 2015]. 
[16]  Historical Inflation Rates for Australia. (2014). [Online]. Available: 
http://www.rateinflation.com/inflation-rate/australia-historical-inflation-rate. [Accessed Janurary 
2015]. 
[17]  Organisation for Economic Co-operation and Development.  Prices and purchasing power 
parities (PPP). OECD: Paris, 2013. [Online]. Available: 
http://www.oecd.org/std/pricesandpurchasingpowerparitiesppp/. [Accessed February 2014]. 
27 
 
[18]  Phillips Z, Ginnelly L, Sculpher M, et al.  Review of guidelines for good practice in decision 
analytic modelling in health technology assessment. Health Technol Assess 2004;  8 (36).  
[19]  National Institute for Health and Care Excellence (NICE).  Guide to the methods of technology 
appraisal. (2008). [Online]. Available: 
http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. [Accessed 
February 2014]. 
[20]  Galani C, Schneider H, Rutten F.  Modelling the lifetime costs and health effects of lifestyle 
intervention in the prevention and treatment of obesity in Switzerland.  Int J Public Health 2007; 
52:372-82. 
[21]  Segal L, Dalton A, Richardson J.  Cost-effectiveness of the primary prevention of non-insulin 
dependent diabetes mellitus. Health Promot Int 1998; 13: 197-209.  
[22]  Ianazzo S, Zaniolo O, Pradelli L.  Economic evaluation of treatment with orlistat in Italian obese 
patients.  Curr Med Res Opin 2008; 24: 63-74.  
[23]  Olsen J, Williang I, Ladelund S, Jorgensen T, Gundgaard J, Sorensen J. Cost-effectiveness of 
nutritional counselling for obese patients and patients at risk of ischemic heart disease.  Int J 
Technol Assess Health Care 2005; 21: 194-202.  
[24] 
 
Maetzel A, Ruof J, Covington M, Wolf A.  Economic evaluation of orlistat in overweight and 
obese patients with type 2 diabetes mellitus. Pharmacoeconomics 2003; 21: 501-12.  
[25] Miners A, Harris J, Felix L, Murray E, Michie S, Edwards P.  An economic evaluation of 
adaptive e-learning devices to promote weight loss via dietary change for people with obesity.  
BMC Health Services Research 2012; 12:190 
[26] Spyra A, Riese A, Rychlik R.  Cost-effectiveness of different programs for weight reduction in 
obese patients with diabetes.  Gesundheitsokönomie & Qualitätsmanagement 2014; 19: 79-84 
 
28 
 
[27]  National Institute for Health and Care Excellence.  Review of Clinical Guideline (CG43) - 
Obesity: the prevention, identification, assessment and management of overweight and obesity in 
adults and children. (2011). [Online]. Available: 
http://www.nice.org.uk/nicemedia/live/11000/57615/57615.pdf. [Accessed February 2014]. 
[28] National Institute for Health and Care Excellence.  Public Health Guidance [PH53] – Managing 
overweight and obesity in adults – lifestyle weight management services. (2014). [Online]. 
Available: http://www.nice.org.uk/guidance/PH53. [Accessed January 2015] 
[29]  Lindstrom P, Peltonen M, Tuomilehto J.  Lifestyle strategies for weight control: experience from 
the Finnish Diabetes Prevention Study.  Proc Nutr Soc 2005; 64: 81-8.  
[30]  Torgerson J, Hauptman J, Boldrin M, Sjostrom L.  XENical in the prevention of diabetes in obese 
subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for 
the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155-61.  
[31]  Stratton I, Adler A, Neil H, et al.  Association of glycaemia with macrovascular and 
microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. 
BMJ 2000; 321 (7258): 405-12.  
[32] McConnon A, Kirk S, Cockroft J, Harvey E, Greenwood D, Thomas J, Ransley J, Bojke L.  The 
internet for weight control in an obese sample: Results of a randomised controlled trial.  BMC 
Health Services Research 2007; 7: 206 
[33]  Anderson K, Odell P, Wilson P, Kannel W.  Cardiovascular disease risk profiles.  Am Heart J 
1991;121: 293-8.  
[34]  National Institute for Health and Care Excellence.  TA22: Orlistat for the treatment of obesity in 
adults. NICE: London, 2001. 
[35]  Hunt K, Wyke S, Gray C, et al.  A gender sensitised weight loss and healthy living programme 
for overweight and obese men delivered by Scottish Premier League football clubs (FFIT): a 
29 
 
pragmatic randomised controlled trial. Lancet 2014; [Online]. Available: 
http://dx/dpo.org/10.1016/S014-6736(13)62420-4. 
 
[36] Dent M, Chrisopoulos S, Mulhall C, Ridler C.  Bariatric surgery for obesity.  Oxford: National 
Obesity Observatory, 2010. 
[37] Picot J, Jones J, Colquilt J. The clinical and cost-effectiveness of bariatric (weight loss) surgery 
for obesity: A systematic review and economic evaluation. 
[38] Dixon J, Zimuet P, Albertit G, Rubino F.  Bariatric surgery: an IDF statement for type 2 diabetes.  
2011 Diabet Med 28 628-42 
[39] Crimieux P, Buchwald H, Shikora S, Ghash A, Yang H, Bussing M,  A study on the economic 
impact of bariatric surgery.  Am J Manag Care 2008 14: 589-596 
[40]  Drummond M, Jerrerson T.  Guidelines for authors and peer reviewers of economic submissions 
to the BMJ. The BMJ Economic working party.  BMJ 1996; 313 (7052): 275.  
 608 
  609 
30 
 
Table 1 Summary of interventions evaluated in the retrieved economics studies 610 
Study Country Population 
group 
evaluated 
Sex 
breakdow
n 
Study  
Setting 
Description of Intervention Description of control / 
comparison 
Galani  
2007 
[20] 
Switz. Overweight or 
obese adults (by 
Swiss 
standards), over 
the age of 25 
with baseline 
BMI score of 
≥27kg/m2 
(overweight) or 
BMI score of ≥ 
33 kg/m2 
(obese) 
Results 
reported for 
men and 
women 
together 
and for 
subgroups 
separately. 
Primary 
care 
Lifestyle intervention, consisting of:  
(i) Healthy Lifestyle advice (adapted on the Finnish 
Diabetes Prevention study [29] to include regular 
physical activity (participants recommended to 
undertake moderate intensity exercise for at least 
30 minutes per day. Participants were also given 
detailed dietary advice, namely to (a) limit intake 
of fat to < 30% of energy consumed and of 
saturated fat to < 10%; (b) to increase fibre to at 
least 15g/1,000Kcal and (c) providing advice 
about specific food types.  
(ii) Ongoing support / counselling / consultations 
consisting of (a) Regular individual consultations 
with a dietician (7 visits to dietician in first year, 
4 visits / year in years 2 and 3); (b) regular one 
hour long group based exercise sessions (n  = 20 
people), 4 classes / month in year 1; 2 classes / 
month in years 2 and 3.  
There was no intervention 
given to overweight subjects.   
 
Obese subjects received less 
intense treatment, compared to 
the intervention group.  
Participants received basic 
dietary counseling (3 
individual visits to the dietician 
in year 1, and once per year for 
years 2 and 3) and group based 
exercise sessions (20 people, 
one hour long sessions), twice 
per month in year 1 and once 
per year in years 2 and 3. 
 
 
Ianazzo  
2008 
[22] 
Italy Population 
based on the 
XENDOS study 
[30] data and 
the Italian obese 
population, with 
a BMI≥30; 
Italian obese 
population, ages 
30-60, base case 
model age 35. 
 
47.7% 
men; 
52.3% 
women  
 
Model 
inputs were 
sex-
specific 
NR but 
assumed 
to be 
primary 
care. 
4 years of treatment with Orlistat, 120mg three times 
per day in combination with low fat reducing diet and 
physical activity advice. 
4 years placebo treatment, 3 
times daily plus the same low 
fat reducing diet and physical 
activity advice. 
Maetzel  
2003 
[24] 
USA Overweight and 
obese adults 
with type 2 
diabetes 
NR, model 
refers to 
age 52 men 
(UKPDS 
[31] study)  
Assumed 
secondary 
care. 
Treatment over an 11 year time horizon: 
Year 1: Orlistat + adherence to guideline therapy 
(ATG)** 
Years 2-11: ATG** only 
Treatment over an 11 year time 
horizon with adherence to 
guidelines** only. 
31 
 
Study Country Population 
group 
evaluated 
Sex 
breakdow
n 
Study  
Setting 
Description of Intervention Description of control / 
comparison 
Olsen  
2005 
[23] 
Denmark Obese patients 
with at least one 
of the 
following: 
BMI≥30kg/m2 
waist circ. > 
102cm (men) 
and >88cm 
(women), 
Dyslipidaemia  
Type 2 
diabetes. 
NR, but 
results 
were 
presented 
based on 
sex-
specific 
cardiovasc
ular risk 
parameters. 
Primary 
care 
(GP / 
Dieticia
n 
clinics) 
GP nutritional counselling: general lifestyle and 
healthy diet advice, (content unspecified).  Intervention 
consisted of 6 counselling sessions over 12 months 
(1x30 mins. + 5x12 mins.).  Patients provided with 
commercially available information on healthy diet. 
 
Dietician nutritional counselling: Provision of detailed 
advice on the principals of good nutrition (restricted 
total dietary energy, reduced fat, and cholesterol 
lowering diet.  6 consultations over 12 months (1x 60 
mins. + 5 x 30 mins.). 
 
Standard care – no active 
intervention. 
Segal 
1998 
[21] 
Australia Persons with 
impaired 
glucose 
tolerance, 
overweight / 
obese men, 
seriously obese 
persons, women 
with previous 
gestational 
diabetes, 
general 
Australian 
population 
Men only* Primary 
care. 
Group behavioural modification for men (5-6 group 
sessions, aim was to reduce waist size through diet 
change and increased activity, empowerment 
philosophy).  Detailed information on intervention 
content was not available. 
Standard care – no active 
intervention. 
Miners, 
2012 
[25] 
UK Obese adults 
with a 
BMI≥30kg/m2 
Base case model 
for average 50 
year old male 
 
Results 
reported by 
sex sub-
group.  
Most other 
analyses on 
men only 
Primary 
care 
An E-learning device, based on that reported in 
McConnon et al, 2007 [32], used to provide advice, 
tools and information to support behavior change in 
dietary and exercise patterns.   
 
 
Based on patient self-management and individualized 
based on their own needs.  Advice was personalized 
and given in response to a series of online questions.  
Motivational statements and emails automatically 
A generic, non-specified 
conventional care package, 
including dietary and exercise 
information.  
 
A crude comparison vs. 
Orlistat was also modelled, 
though not formally presented.  
Purpose was contextual only. 
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provided, especially to those not visiting the site often.  
12 months subscription to site. 
Study Country Population 
group 
evaluated 
Sex 
breakdow
n 
Study  
Setting 
Description of Intervention Description of control / 
comparison 
Spyra, 
2014 
[26] 
Germany 55 year old 
male with a 
BMI≥30kg/m2 
who has already 
developed Type 
II Diabetes 
Results 
applicable 
to a 55 year 
old male 
Not 
clear – 
assume 
primary 
care / 
comm. 
program
me. 
4 interventions: 
A) Body-Med nutrition concept:  2 phase programme, 
phase 1 included the use of protein rich meal 
replacements.  Phase 2 focused on maintenance with 
medically controlled long term care (details not 
provided).  Other components included behavioural 
therapy and exercise.  Programme carried out by 
specially trained professionals.  Frequency of delivery / 
contact not reported. 
 
B) MOBILIS Programme: an interdisciplinary training 
programme centered on exercise, psychology, nutrition 
and medicine.  Details on content not reported.  
Programme duration: 1 year; Frequency of contact not 
reported. Provided by specially trained medical and 
non-medical professionals. 
 
C) DGE (‘I am Losing Programme’):  High 
carbohydrate, low fat diet (no solid food plans), 3 
month programme can be carried out in structured 
groups or on one’s own.  Participants follow a 12 step 
manual to a healthy diet.  Physical exercise is also 
incorporated. 
 
D) Therapeutic Nihilism:  No medically attended or 
structured programme but tries to lose weight on their 
own.  Patients provided with basic guidance on healthy 
eating, diet and exercise only.  Not medically or 
professionally supervised in any way. 
None reported, though it could 
be assumed that the therapeutic 
Nihilism could be considered a 
baseline comparator.  
However, results are not 
presented in this way. 
*A total of five alternative programmes were evaluated in the study, however as only programme IV presented results specific to men, the others have not been 611 
included.   612 
** ATG = adherence to guidelines; standard pharmacotherapy for type 2 diabetes (e.g. metformin) and weight management (diet and physical activity) 613 
ATG = Adherence to Guidelines; BMI = Body Mass Index; DGE:  Deutsche Gesellschaft für Ernählung (translated from German as the German Society for 614 
Nutrition); GP = General Practitioner; Mg. = Milligrams; Mins = Minutes; MOBILIS: Multizentrisch Organisierte Bewegungsorientierte Initiative zur 615 
Lebensstiländerung In Selbstverantwortung (translated from German as a Multi-centre movement oriented initiative for lifestyle change through self-616 
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responsibility); NR = Not Reported; UKPDS = United Kingdom Prevention of Diabetes Study; XENDOS = XENical for the preventions of Diabetes in Obese 617 
Subjects. 618 
  619 
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Table 2 Detailed cost and outcome data from the studiesA 620 
Study Int. Comp. Model 
Time 
Horizon 
Currenc
y (year) 
Base 
case 
discount 
rates 
Primary 
economi
c 
outcome 
measure 
Inc. costs,  
Study 
currency 
(2014 
GBP)F 
Inc. 
Outcom
es F  
ICER; 
study 
currency 
(2014 
GBP) F 
ICER 
range 
from 
sensitivity 
analyses 
study 
currency 
(2014 
GBP) F 
Results from probabilistic 
sensitivity analysis (if 
applicable) 
Galani 
2007 
[20] 
Lifestyle  O/W 
group 
(std. 
care); 
obese 
group 
(lifestyle 
advice) 
60 years 
or to max 
age of 
85. 
Swiss 
francs 
(CHF), 
(2006). 
Costs – 
3% 
Effects – 
3% 
QALY O/W: 
+405(+£204
) 
B/L: -6(-£3) 
OB:+127 
(+£64) 
O/W: 
+0.25 
B/L: 
+0.28 
OB: 
+0.29 
NR for all 
age 
groups, 
calc as: 
O/W: 
1,620 
(£816) 
B/L: 
Dominant 
OB: 438 
(£220)C 
Dominant 
to +2,014 
(£1,014) 
Data only presented for B/L 
obesity. 
57% probability of cost-
effectiveness (35 year old male) to 
72% probability (55 year old 
male) at a willingness to pay of 0 
CHF per QALY gained. 
92% probability of cost-
effectiveness (35 year old male) to 
98% probability (55 year old 
male) at a willingness to pay of 
1000 CHF per QALY gained. 
Ianazz
o 2008 
[22] 
Orlistat + 
lifestyle  
Placebo+ 
lifestyle  
10 years Euro, 
(2007)B 
Costs – 
3.5% 
Effects – 
3.5% 
QALY +2,931 
(£2,850) 
+0.046 74,290 
(£72,249) 
M only: 
NR 
M+W: 
10,160 
(£9,881) to 
79110 
(£76,937) 
Men only: NR.  Men and Women: 
15% probability of cost-
effectiveness at a willingness to 
pay of €45,000 per QALY gained 
(base case analysis), increasing to 
99% probability for a subgroup 
with IGT. 
 
Maetz
el 
2003 
[24] 
Orlistat + 
standard 
treatment 
guidelines 
Standard 
treatment 
guideline
s alone. 
11 years USD 
(2001) 
Costs – 
3% 
Effects – 
3% 
Event 
free life 
years 
gained 
+1,099 
(£1,008) 
+0.162 +8,327 
(£7,553) 
+8,327 
(£7,553) to 
+25,827 
(£23,426) 
95% probability of cost-
effectiveness at a willingness to 
pay of $20,000 (i.e. £18,140) per 
event free life year gained, 
assuming continuation of 
treatment effect over 3 years. 
 
95% probability of cost-
effectiveness at a willingness to 
pay of $68,000 (£61,674) per 
event free life year gained, 
assuming continuation of 
treatment effect for 1 year only.” 
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Study Int. Comp. Model 
Time 
Horizon 
Currenc
y (year) 
Base 
case 
discount 
rates 
Primary 
economi
c 
outcome 
measure 
Inc. costs,  
Study 
currency 
(2014 
GBP)F 
Inc. 
Outcom
es F  
ICER; 
study 
currency 
(2014 
GBP) F 
ICER 
range 
from 
sensitivity 
analyses 
study 
currency 
(2014 
GBP) F 
Results from probabilistic 
sensitivity analysis (if 
applicable) 
Olsen 
2005 
[23] 
GP or 
dietician 
counselling 
Standard 
care  
Costs – 1 
year 
Effects – 
up to age 
80. 
Danish 
Kroner 
(2001) 
Costs – 
none 
Effects – 
5% 
Life 
years 
gained 
Diet: 1,684 
(£190) 
GP: 774 
(£87) 
Diet: 
0.0002 
GP: 
0.1210 
Diet: NR, 
calc as 
8.42m 
(£949,227) 
GP: 6,399 
(£640) 
Diet: 
26,730 
(£3,013) to 
6.155m 
(£687,682) 
GP: 3,240 
(£365) to 
24,037 
(£2,710) 
N/A 
Segal 
1998 
[21]D 
Group 
behavior 
modification 
Standard 
care 
25 years 
post 
interventi
on 
Australia
n Dollars 
(1997) 
Costs – 
5% 
Effects – 
5% 
Life 
years 
gained 
Prog IV  
Intervention 
cost = 577 
(£380) 
Total cost: 
NR 
Prog IV 
MixedD 
GT: 
+111E 
IGT: 
+138E 
Prog IV 
(net costs) 
MixedD 
GT: 
Dominant  
IGT: 
Dominant 
 
Prog IV 
Dominant 
to 1,600  
(£1,054) 
N/A 
Miners
, 2012 
[25] 
E- learning 
device 
Standard 
care 
(conventi
onal care 
package) 
Life time GBP 
(2009) 
Costs – 
3.5% 
Effects – 
3.5% 
QALY +£762 
(+£880) 
+0.007 £102,112 
(£117,963) 
Dominant 
to 
£232,911 
(£269,067) 
<50% probability of the E-
learning device being cost 
effective up to a WTP of £200,000 
/ QALY gained. 
Spyra, 
2014 
[26] 
A) Bodymed 
– nutrition 
B) 
MOBILIS 
C) DGE (‘I 
am losing’) 
D) Nihilism 
None 
stated 
(Assume 
no care) 
3 years EUR 
(2012) 
Costs – 
3% 
Effects – 
NR 
De novo 
effect 
score 
(based 
on 
weight 
and 
clinical 
events) 
A) 3,595 
(£2,997) 
B) 4,248 
(£3,541) 
C) 3,704 
(£3,088) 
D) 3,696 
(£3,081) 
A) 3.75 
B) 2.55 
C) 1.90 
D) 1.17 
A) 957 
(£798) 
B) 1,669 
(£1,391) 
C) 1,948 
(£1,624) 
D) 3,172 
(£2,644) 
NR NR 
 AResults are for men only, unless otherwise stated; BYear 2007 costing assumed based on reference lists for unit costs; CBased on author calculations from 621 
included studies; DProgramme IV results for men only, presumed a mix of normal glucose tolerance, impaired glucose tolerance and type 2 diabetes;  ECohort 622 
size of 100 patients; F ICERs may not always = incremental costs / incremental outcomes in the table above.  This is due to the potential for rounding errors in 623 
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calculations.  Data reported for ICERs are as reported in the studies.  B/L = Borderline; CHF= Swiss Francs; DGE:  Deutsche Gesellschaft für Ernählung 624 
(translated from German as the German Society for Nutrition); GBP = Great British Pounds; GP = General Practitioner; ICER = Incremental cost-625 
effectiveness ratio; IGT= Impaired Glucose Tolerance; Inc. = Incremental; M= Men; MOBILIS: Multizentrisch Organisierte Bewegungsorientierte Initiative zur 626 
Lebensstiländerung In Selbstverantwortung (translated from German as a Multi-centre movement oriented initiative for lifestyle change through self-627 
responsibility); N/A = Not applicable; NR = Not Reported; OB = Obese; O/W = overweight; QALY = Quality Adjusted Life Year; USD = US dollars; W = 628 
Women; WTP = Willingness to Pay 629 
 630 
  631 
37 
 
Supplementary Table 3:  Quality assessment of studies (based on Phillips checklist [18]) 632 
Study name and year: 
Galani 
2007 [20] 
Ianazzo  
2008 [22] 
Maetzel  
2003 [24] 
Olsen  
2005 [23] 
Segal  
1998 [21]  
Miners 
2012 [25] 
Spyra 
2014 [26] 
Quality 
Criterion 
Dimension of 
Quality 
Question 
Response Response Response Response Response Response Response 
Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? 
Structure:   
S1 
Statement of 
decision 
problem / 
objective 
Clear statement of the 
decision problem? 
Y Y Y Y Y Y Y 
    
Is the objective of the 
evaluation and model 
specified and consistent 
with the stated decision 
problem? 
 
Y Y Y Y Y Y Y 
    
Is the primary decision 
maker specified? 
N N N N N Y Y 
S2 
Statement of 
scope / 
perspective 
Is the perspective of the 
model clearly stated? 
Y Y Y ? Y Y Y 
    
Are the model inputs 
consistent with the stated 
perspective? 
 
N N Y N Y Y Y 
    
Has the scope of the model 
been stated and justified? 
Y Y N N Y Y Y 
    
Are the outcomes of the 
model consistent with the 
perspective, scope and 
overall objective of the 
model? 
Y Y Y ? ? Y Y 
S3 
Rationale for 
structure 
Is the structure of the model 
consistent with a coherent 
theory of the health 
condition under evaluation? 
Y Y Y N Y Y Y 
    
Are the sources of data used 
to develop the structure of 
the model specified? 
Y Y N N N Y N 
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Are the causal relationships 
described by the model 
structure justified 
appropriately? 
Y Y Y Y N Y Y 
Study name and year: 
Galani 
2007 [19] 
Ianazzo 
2008 [21] 
Maetzel  
2003 [23] 
Olsen  
2005 [22] 
Segal  
1998 [20]  
Miners 
2012 [25] 
Spyra 
2014 [26] 
Quality 
Criterion 
Dimension of 
Quality 
Question 
Response Response Response Response Response Response Response 
Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? 
S4 
Structural 
assumptions 
Are the structural 
assumptions transparent and 
justified? 
Y Y Y ? Y Y N 
    
Are the structural 
assumptions reasonable 
given the overall objective, 
perspective and scope of the 
model? 
Y Y Y N Y Y Y 
S5 
Strategies / 
Comparators 
Is there a clear definition of 
the options under 
evaluation? 
Y Y Y Y ? Y Y 
    
Have all feasible and 
practical options been 
evaluated? 
Y Y Y Y Y Y Y 
    
Is there justification for the 
exclusion of feasible 
options? 
N/A N/A N/A N/A Y N/A N/A 
S6 Model type 
 
Is the chosen model type 
appropriate given the 
decision problem and 
specified causal 
relationships within the 
model? 
 
Y Y Y N Y Y Y 
S7 Time horizon 
 
Is the time horizon of the 
model sufficient to reflect 
all important differences 
between options? 
 
Y ? ? N Y Y N 
     Y Y Y Y/N ? Y N 
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Are the time horizon of the 
model, the duration of 
treatment and the duration 
of treatment effect described 
and justified? 
 
Study name and year: 
Galani 
2007 [19] 
Ianazzo 
2008 [21] 
Maetzel  
2003 [23] 
Olsen  
2005 [22] 
Segal  
1998 [20]  
Miners 
2012 [25] 
Spyra 
2014 [26] 
Quality 
Criterion 
Dimension of 
Quality 
Question 
Response Response Response Response Response Response Response 
Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? 
S8 
Disease states / 
pathways 
Do the disease states (state 
transition model) or the 
pathways (decision tree 
model) reflect the 
underlying biological 
process of the disease in 
question and the impact of 
interventions? 
 
Y Y Y N/A Y Y Y 
S9 Cycle length 
Is the cycle length defined 
and justified in terms of the 
natural history of disease? 
 
Y Y Y/N N/A Y/N NA Y/N 
Data:   
D1 
Data 
identification 
 
Are the data identification 
methods transparent and 
appropriate given the 
objectives of the model? 
 
Y/N Y/N Y Y ? Y Y 
    
Where choices have been 
made between data sources, 
are these justified 
appropriately? 
N ? N ? ? Y N 
    
Has particular attention 
been paid to identifying 
data for the important 
parameters in the model? 
Y Y/N Y Y Y Y ? 
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Has the quality of the data 
been assessed 
appropriately? 
Y Y ? N N N N 
    
Where expert opinion has 
been used, are the methods 
described and justified? 
N/A N/A N/A N/A N NA NA 
Study name and year: 
Galani 
2007 [19] 
Ianazzo 
2008 [21] 
Maetzel  
2003 [23] 
Olsen  
2005 [22] 
Segal  
1998 [20]  
Miners 
2012 [25] 
Spyra 
2014 [26] 
Quality 
Criterion 
Dimension of 
Quality 
Question 
Response Response Response Response Response Response Response 
Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? 
D2 Data modelling 
Is the data modelling 
methodology based on 
justifiable statistical and 
epidemiological 
techniques? 
Y Y Y Y Y Y Y 
D2a Baseline data 
Is the choice of baseline 
data described and 
justified? 
 
Y Y Y Y Y/N Y Y 
    
Are transition probabilities 
calculated appropriately? 
 
? Y ? N/A ? NA Y 
    
Has a half cycle correction 
been applied to both cost 
and outcomes? 
 
N/Y N N N/A N NA ? 
    
If not, has this omission 
been justified? 
 
N/A N N N/A N NA N 
D2b Treatment effects 
 
If relative treatment 
effects have been derived 
from the trial data, have 
they been synthesized 
using appropriate 
techniques? 
 
Y Y ? ? ? Y ? 
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Have the methods and 
assumptions used to 
extrapolate short term 
results to final outcomes 
been documented and 
justified? 
Y Y Y Y Y Y Y 
    
Have alternative 
extrapolation assumptions 
been explored through 
sensitivity analysis? 
N N Y N N Y N 
Study name and year: 
Galani 
2007 [19] 
Ianazzo 
2008 [21] 
Maetzel  
2003 [23] 
Olsen  
2005 [22] 
Segal  
1998 [20]  
Miners 
2012 [25] 
Spyra 
2014 [26] 
Quality 
Criterion 
Dimension of 
Quality 
Question 
Response Response Response Response Response Response Response 
Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? 
    
Have assumptions 
regarding the continuing 
effect of treatment once 
treatment is complete been 
documented and justified? 
Y Y Y Y/N Y Y Y 
    
Have alternative 
assumptions regarding the 
continuing effect of 
treatment been explored 
through sensitivity 
analysis? 
N N Y N Y Y N 
D2c Costs 
Are the costs incorporated 
into the model justified? 
Y Y Y N Y Y Y 
    
Has the source for all 
costs been described? 
Y Y Y Y Y Y Y 
    
Have discount rates been 
described and justified 
given the target decision-
maker? 
Y Y Y Y Y Y Y 
D2d 
Quality of life 
weights (utilities) 
Are the utilities 
incorporated into the 
model appropriate? 
? Y N/A N/A N/A Y N/A 
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Is the source for the utility 
weights referenced? 
Y Y N/A N/A N/A Y N/A 
    
Are the methods of 
derivation for the utility 
weights justified? 
? ? N/A N/A N/A N N/A 
D3 
Data 
incorporation 
Have all data incorporated 
into the model been 
described and referenced 
in sufficient detail? 
 
Y Y Y Y Y/N Y N 
Study name and year: 
Galani 
2007 [19] 
Ianazzo 
2008 [21] 
Maetzel  
2003 [23] 
Olsen  
2005 [22] 
Segal  
1998 [20]  
Miners 
2012 [25] 
Spyra 
2014 [26] 
Quality 
Criterion 
Dimension of 
Quality 
Question 
Response Response Response Response Response Response Response 
Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? 
    
Has the use of mutually 
inconsistent data been 
justified (i.e. are 
assumptions and choices 
appropriate)? 
N/A N/A N/A N/A N/A Y N/A 
    
Is the process of data 
incorporation transparent? 
Y Y Y Y N Y Y 
    
If data have been 
incorporated as 
distributions, has the 
choice of distribution for 
each parameter been 
described and justified? 
Y Y N/A N/A N/A ? N/A 
    
If data have been 
incorporated as 
distributions, is it clear 
that second order 
uncertainty is reflected? 
Y Y Y N/A N/A Y N/A 
D4 
Assessment of 
uncertainty 
Have the four principal 
types of uncertainty been 
addressed? 
N N N N N N N 
    
If not, has the omission of 
particular forms of 
uncertainty been justified? 
N N Y N N N N 
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D4a Methodological 
Have methodological 
uncertainties been 
addressed by running 
alternative versions of the 
model with different 
methodological 
assumptions? 
Y Y Y Y N Y N 
D4b Structural 
Is there evidence that 
structural uncertainties 
have been addressed via 
sensitivity analysis? 
N N Y N Y N N 
D4c Heterogeneity 
Has heterogeneity been 
dealt with by running the 
model separately for 
different subgroups? 
Y Y N Y Y Y N 
Study name and year: 
Galani 
2007 [19] 
Ianazzo 
2008 [21] 
Maetzel  
2003 [23] 
Olsen  
2005 [22] 
Segal  
1998 [20]  
Miners 
2012 [25] 
Spyra 
2014 [26] 
Quality 
Criterion 
Dimension of 
Quality 
Question 
Response Response Response Response Response Response Response 
Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? Y/N/NA/? 
D4d Parameter 
Are the methods of 
assessment of parameter 
uncertainty appropriate? 
Y Y Y Y ? Y N 
    
If data are incorporated as 
point estimates, are the 
ranges used for sensitivity 
analysis stated clearly and 
justified? 
N Y Y N/A Y Y N 
Consistency:   
C1 
Internal 
consistency 
Is there evidence that the 
mathematical logic of the 
model has been tested 
thoroughly before use? 
N Y N N N N N 
C2 
External 
consistency 
Are any counterintuitive 
results from the model 
explained and justified? 
Y N/A N/A N/A N/A Y N 
    
If the model has been 
calibrated against 
independent data, have 
Y Y N N/A N Y N 
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any differences been 
explained and justified? 
    
Have the results of the 
model been compared 
with those of previous 
models and any 
differences in results 
explained? 
Y Y Y Y N Y N 
 633 
 634 
 635 
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Appendix 1: Cost-effectiveness search strategies – MEDLINE and Embase 637 
MEDLINE (1946 to 24 October 2014); 638 
MEDLINE In-Process & Other Non-Indexed Citations (24 October 2014);  639 
EMBASE (1974 to October 2014) 640 
Ovid multifile search: http://shibboleth.ovid.com/ 641 
 642 
1. exp “costs and cost analysis”/ 643 
2. cost-benefit analysis/ 644 
3. quality-adjusted life years/ 645 
4. economics,pharmaceutical/ 646 
5. exp budgets/ 647 
6. exp models, economic/ 648 
7. exp decision theory/ 649 
8. monte carlo method/ 650 
9. markov chains/ 651 
10. exp health status indicators/ 652 
11. cost$.ti. 653 
12. (cost$ adj2 (effective$ or utilit$ or benefit$ or minimis$)).ab. 654 
13. economic$ model$.tw. 655 
14. (economic$ or pharmacoeconomic$ or pharmaco-economic$).tw. 656 
15. (price$ or pricing).tw. 657 
16. (financial or finance or finances or financed).tw. 658 
17. ((value adj2 money) or monetary).tw. 659 
18. markov$.tw. 660 
19. monte carlo.tw. 661 
20. (decision$ adj2 (tree? or analy$ or model$)).tw. 662 
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21. (standard adj1 gamble).tw. 663 
22. trade off.tw. 664 
23. or/1–22 665 
24. *obesity/ 666 
25. *overweight/ 667 
26. obesity, morbid/ use prmz 668 
27. morbid obesity/ use oemez 669 
28. (obes$ or overweight).tw. 670 
29. weight loss/ use prmz 671 
30. weight reduction/ use oemez 672 
31. (weight adj1 (los$ or reduc$ or maint$ or control or manag$)).tw. 673 
32. (obesity adj1 management).tw. 674 
33. (anti obesity or antiobesity).tw. 675 
34. or/24–32 676 
35. (men or male or males).tw. 677 
36. *obesity/ec 678 
37. *overweight/ec 679 
38. or/36-37 680 
39. (women not men).tw. 681 
40. (female not male).tw. 682 
41. 38 not (39 or 40) 683 
42. 23 and 34 and 35 684 
43. 41 or 42 685 
44. exp animals/ not humans/ 686 
45. 43 not 44 687 
46. (rat or rats).tw. 688 
47 
 
47. 45 not 46 689 
48. limit 47 to (“all infant (birth to 23 months)” or “all child (0 to 18 years)” or “all adult (19 plus years)” 690 
or “newborn infant (birth to 1 month)” or “infant (1 to 23 months)” or “preschool child (2 to 5 691 
years)” or “child (6 to 12 years)” or “adolescent (13 to 18 years)”) 692 
49. limit 47 to (embryo or infant or child or preschool child <1 to 6 years> or school child <7 to 12 693 
years>or adolescent <13 to 17 years>) 694 
50. 47 not 48 695 
51. 47 not 49 696 
52. 50 or 51 697 
53. limit 52 to yr=”2009 -Current” 698 
54. remove duplicates from 53 699 
55. (letter or editorial or comment or note).pt. 700 
56. 54 not 55 701 
 702 
 703 
